Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP-4) inhibitor primarily indicated for the management of type 2 diabetes mellitus, where it works to improve glycemic control by increasing insulin… Read more
![Chemical structure of 3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,3,6-trifluorophenyl)butan-1-one phosphate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F3094994-82-5-3-Amino-1-3-trifluoromethyl-56-dihydro-124triazolo43-apyrazin-78H-yl-4-236-trifluorophenylbutan-1-one-phosphate.png&w=3840&q=75)



Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP-4) inhibitor primarily indicated for the management of type 2 diabetes mellitus, where it works to improve glycemic control by increasing insulin levels and suppressing glucagon secretion. This category provides access to high-quality pharmaceutical reference standards essential for analytical testing and quality control within regulated laboratories. These materials, including the active pharmaceutical ingredient, potential process-related or degradant impurities, and stable isotope-labelled compounds, are critical for accurate impurity profiling and method validation. Laboratories utilize these reference standards to ensure the consistency, safety, and regulatory compliance of drug products throughout the manufacturing and development lifecycle. By facilitating precise identification and quantification of impurities in complex matrices, these compounds support the robust analytical standards required for the ongoing monitoring and characterization of sitagliptin phosphate-based therapies.